<DOC>
	<DOCNO>NCT00003392</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness high-dose chemotherapy peripheral stem cell transplantation treat patient recurrent refractory metastatic breast cancer .</brief_summary>
	<brief_title>High-Dose Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Recurrent Refractory Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect 2 year progression-free survival regimen consist cyclophosphamide , paclitaxel , filgrastim ( G-CSF ) mobilize peripheral blood progenitor cell ( PBPCs ) , follow 2 course carboplatin paclitaxel follow 1 course melphalan , support PBPCs G-CSF , patient recurrent refractory , advance breast cancer . II . Evaluate feasibility administer multiple course high dose chemotherapy outpatient set patient . III . Evaluate rate complete response high dose therapy patient . OUTLINE : This multicenter study . Patients receive mobilization therapy consist cyclophosphamide IV 1 hour follow paclitaxel IV 3 hour , filgrastim ( G-CSF ) begin 24 hour follow completion paclitaxel continue last day leukapheresis . Leukapheresis continue adequate number CD34+ cell collect . Following cell count recovery , patient receive 3 course high-dose chemotherapy : 2 course paclitaxel IV 3 hour follow carboplatin IV 1 hour , first course generally within 21 day completion leukapheresis second course 21-35 day first ; 1 course melphalan IV infuse 30 minute 21-35 day previous carboplatin dose . Each course chemotherapy follow 24-48 hour later infusion G-CSF-mobilized peripheral blood progenitor cell G-CSF . Patients follow every 3 month 2 year . PROJECTED ACCRUAL : A total 96 evaluable patient accrue study 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent refractory , metastatic breast cancer Patients previously treat metastatic disease must show response last standard dose chemotherapy regimen within 60 day study entry OR Patients evidence disease ( e.g. , resected skin lesion ) must show evidence progression bone disease No CNS metastases No disease progression follow prior platinum paclitaxel base regimens Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 65 Sex : Not specify Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 90,000/mm3 No prior inability mobilize adequate peripheral blood progenitor cell high dose therapy Hepatic : Bilirubin great 1.8 mg/dL Transaminases stable great 3 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : LVEF within normal limit No significant cardiovascular disease No coronary artery disease No arrhythmias No congestive heart failure Other : Not pregnant nursing Negative pregnancy test require fertile woman Effective contraception require fertile patient Not HIV positive No nonmalignant disease preclude protocol treatment No sensitivity E. coliderived drug preparation No prior participation study No great grade I neurotoxicity PRIOR CONCURRENT THERAPY : Biologic therapy : No prior cellular support high dose chemotherapy Chemotherapy : See Disease Characteristics No 6 prior course chemotherapy metastatic disease At least 3 week since prior chemotherapy recover No prior high dose chemotherapy cellular support Endocrine therapy : No concurrent steroid therapy Concurrent hormonal therapy allow Radiotherapy : At least 3 week since prior radiotherapy recover No prior extensive pelvic radiation Surgery : Not specify Other : Recovered acute toxic effect prior therapy No concurrent anticoagulation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>